A phase 1, safety assessment and pharmacokinetic study of IPI-504 in patients with relapsed, and relapsed refractory multiple myeloma
Phase of Trial: Phase I
Latest Information Update: 24 Aug 2018
At a glance
- Drugs Retaspimycin (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- 06 Sep 2005 New trial record.